Efficacy and Safety of Directly Acting Antivirals in Patients with Hepatitis C Infection on Hemodialysis.

Introduction: The high prevalence of hepatitis C virus (HCV) infection among patients on maintenance hemodialysis (MHD) has been reported in India. Due to the strong association of HCV infection with death and cardiovascular disease, it is important to treat the infection. However, treatment poses a challenge since only a few directly acting antivirals recommended in the guidelines for HCV treatment in the dialysis population are available in India. Pangenotypic sofosbuvir has concerns about its safety due to its renal elimination.
Materials and Methods: This prospective study was undertaken between 2019 and 2020 among patients on hemodialysis with HCV infection. Clinical details, biochemical parameters, viral load, and genotyping were recorded and the outcome of treatment with sofosbuvir in combination with velpatasvir/daclatasvir for 12 weeks was noted. Descriptive and inferential statistical analysis was carried out. The Chi-squared/Fisher exact test was used.
Results: In the present study, 54 hemodialysis patients with HCV were treated with full doses of sofosbuvir and velpatasvir/daclatasvir. Genotype 1 was the most common, seen in 75.9% (n = 41). Around 96.29% (n = 52) of patients achieved sustained virological response (SVR) at the end of the study. None of the patients experienced serious side effects requiring dose reduction or discontinuation of the treatment.
Conclusion: Sofosbuvir combination therapy offers an excellent response in dialysis patients irrespective of the genotype and presence of cirrhosis with minimal monitoring as in non-chronic kidney disease (CKD) patients.
(© Journal of the Association of Physicians of India 2011.)